Stop TB Partnership Nigeria is the multi-stakeholder partnership dedicated to complement the efforts of the government and other stakeholders to end the scourge of TB in Nigeria. It fulfils its mandate by advocating for increased political commitment, support and funding that such a significant challenge deserves. The Partnership comprises of government, parliamentarians, multilateral and bilateral organizations, development partners, private sector, academia, professional associations, civil society organizations, media and persons affected by TB.
Stop TB Partnership Nigeria is affiliated to the Global Stop TB Partnership, Geneva. It supported the establishment and also coordinates the activities of Nigeria Parliamentary TB Caucus – a platform for increasing political commitment to end TB in Nigeria and TB People Nigeria – a
platform for increasing the engagement of people infected and affected by TB TB.
Tuberculosis (TB) is among the top priority diseases in Nigeria, as the country is one of 10 high burden countries for TB, TB/HIV and multi-drug resistant (MDR)-TB in 2021i as stated in the Global TB Report by World Health Organization (WHO). Nigeria has an estimated 440,000 TB cases, of which only 117,320 were diagnosed and notified. Despite incremental progress in the quality of TB treatment and care over the years as evidenced by the 87% treatment success rate and 91% uptake of antiretroviral therapy (ART) among HIV-positive TB patients, the overall TB treatment coverage remains low at 27% in 2021, and case notifications have marginally increased in the past five years. This situation translates to about 75% of TB patients being missed annually. Of equally great concern is the increasing gap in access to TB services to the pediatric population and other vulnerable groups.
Also, people who have TB are usually more vulnerable to other infections including being at a higher risk of developing complications from COVID-19 due to pre-existing lung damage. The COVID-19 Pandemic has had varying short and long-term impacts on global health and including TB services and Nigeria is not an exception. Some of the direct effects on the TB Programme reported in countries around the world include the disruption of access to TB
services as a result of prolonged periods of lockdown, treatment interruption potentially breeding drug-resistance, as well as the effects of stigma for both healthcare workers and clients amongst many others. The COVID-19 pandemic has severely disrupted TB responses, stalling and reversing years of progress made against TB. In 2020, COVID-19 overtook TB globally as the most common cause of death from an infectious disease, but in low- and middle-income countries, TB deaths still remain far higher than those from COVID-19. As the number of people vaccinated against COVID-19 grows, the number of COVID-19 deaths will decrease while on daily basis, TB will continue to kill about 4,000 people globally and 432 people in Nigeria
Funding constraints have remained the key challenge towards ending TB in Nigeria. Over the years, TB financing has been driven largely by external funding sources. In 2020, it was estimated that the implementation of National Strategic Plan (NSP), for tuberculosis, required about $384 million USD, only 30% was available to all the implementers of TB control activities in Nigeria (7% domestic and 23% donor funds), with 70% funding gap